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Disease
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Gram-positive bacteria
92 known serotypes
Polysaccharide capsule                                       
important virulence 
factor
Type-specific antibody 
is protective
Limited cross-reactivity
Streptococcus pneumoniae
Second most common cause of vaccine-
preventable disease in the U.S. 
Major clinical syndromes
• Pneumonia
• Bacteremia
• Meningitis
Pneumococcal Disease
https://www.cdc.gov/pneumococcal/clinicians/clinical-features.html
Invasive Pneumococcal Disease
Incidence by Age Group–2017*
*CDC Active Bacterial Core surveillance 2017 report: 
http://www.cdc.gov/abcs/reports-findings/survreports/spneu17.html
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Age Group (Yrs)
invasive pneumococcal disease (IPD) among children <5 
years old, 1998--2016, United States
https://www.cdc.gov/pneumococcal/surveillance.html
Trends in Invasive Pneumococcal Disease among 
Adults 19–64 Years of Age, 1998–2016
https://www.cdc.gov/pneumococcal/surveillance.html
Trends in Invasive Pneumococcal Disease among Adults 65 
Years of Age and Older, 1998–2016
http://www.cdc.gov/abcs/reports-findings/survreports/spneu-types.html
https://www.cdc.gov/pneumococcal/surveillance.html
Functional or anatomic asplenia, including 
sickle-cell disease
Altered immunocompetence 
Underlying medical conditions, including 
chronic renal disease, nephrotic syndrome, 
and CSF leak
Cochlear implant
Risk Factors for Invasive Pneumococcal Disease
 Reservoir Human carriers
 Transmission Respiratory and
autoinoculation
 Temporal pattern Winter and early spring
 Communicability Unknown; 
probably as long as organism 
in respiratory secretions
Pneumococcal Disease Epidemiology
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3-7 fold increased risk
20 fold increased risk
Unpublished data, Active Bacterial Core surveillance, 2009
Incidence of IPD in Adults Age 18–64 Years with Selected 
Underlying Conditions, United States, 2009
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Vaccines
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 1977  14-valent polysaccharide vaccine 
licensed
 1983  23-valent polysaccharide vaccine 
licensed (PPSV23)
 2000  7-valent polysaccharide conjugate 
vaccine licensed (PCV7)
 2010  13-valent polysaccharide conjugate 
vaccine licensed (PCV13)
Pneumococcal Vaccines
Pneumococcal Vaccine Products
Vaccine product Age indications
Pneumococcal Polysaccharide Vaccine
Pneumovax 23 (PPSV23) 50 years of age or older and persons 
age ≥2 years who are at increased 
risk for pneumococcal disease
Pneumococcal Conjugate Vaccine
Prevnar 13 (PCV13) Children: 6 weeks–18 years
Adults: 19 years and older
PCV7 Introduction among U.S. Children and 
Its Impact on Invasive Pneumococcal Disease
Moore, IDSA, 2009, and CDC, unpublished data 
PCV7 introduced into routine schedule 2000
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Rates of IPD among Children <5 yrs old
Overall -76 (-79,-73)
PCV7 type -100 (-100,-99)
In 2008, 61% of invasive pneumococcal 
disease cases among children younger than 5 
years were attributable to the serotypes 
included in PCV13
Pneumococcal Conjugate Vaccine 
(PCV13) in Children
In 2013, 20%–25% of invasive pneumococcal 
disease cases among adults 65 years old and 
older were attributable to PCV13 serotypes
10% of community-acquired pneumonia in 
adults due to PCV13 serotypes
Pneumococcal Conjugate Vaccine 
(PCV13) in Adults 
Most estimates range between 60%–70% 
effective against invasive disease among 
immunocompetent older persons and adults 
with underlying illnesses
Effectiveness among immunocompromised or 
very old persons not demonstrated
Pneumococcal Polysaccharide Vaccine (PPSV23) 
Immunogenicity/Effectiveness
Highly immunogenic in infants and young 
children, including those with high-risk 
medical conditions
PCV7 was 97% effective against invasive 
disease caused by vaccine serotypes 
(presumably PCV13 as well)
Pneumococcal Conjugate Vaccine 
(PCV13) Immunogenicity/Efficacy
New Evidence Supporting PCV13 Use among 
Adults, CAPiTA Results
CAPiTA, ACIP, June 2014
Study/Population Endpoint
Vaccine Efficacy 
(95% CI)
CAPiTA
~85,000 Adults 65+
Netherlands
PCV13-serotype IPD 75% (41%, 91%)
PCV13-serotype 
nonbacteremic
pneumonia 45% (14%, 65%)
Clinical 
Considerations
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Routinely recommended for infants and children 2 through 59 
months of age 
• 4 doses at 2, 4, 6, and 12 to 15 months
• Fewer doses if series started at 7 months of age or older
Children who have received 1 or more doses of PCV7 should 
complete the immunization series with PCV13
ACIP PCV13 Vaccine Recommendations: Pediatric
Age at First Dose # of Doses Booster
7–11 months 2 doses Yes
12–23 months 2 doses* No
24–59 months 1 dose No
24–71 months, 
with medical
conditions**
2 doses* No
Pneumococcal Conjugate Vaccination Schedule for 
Unvaccinated Older Children:  Primary Series 
*Separated by at least 8 weeks; see MMWR 2010;59(RR-11):1–19, at 
https://www.cdc.gov/mmwr/pdf/rr/rr5911.pdf
**Chronic heart, lung disease, diabetes, CSF leak, cochlear implant, sickle cell disease, other 
hemoglobinopathies, functional or anatomic asplenia, HIV infection, immunocompromising 
conditions
ACIP recommended use of PCV13 for immunocompromised 
persons 6 years and older (2012, 2013)
ACIP recommended use of PCV13 for all adults 65 years or 
older in 2014
PCV13
A dose of PCV13 should be administered to children 6 through 
18 years of age who are at increased risk for invasive 
pneumococcal disease* (and no prior PCV13 doses)
• Functional or anatomic asplenia, including sickle cell disease
• HIV infection and other immunocompromising conditions
• Cochlear implant
• CSF leak
Regardless of previous history of PCV7 or PPSV vaccine
ACIP Recommendations for PCV13 Dose
*Off-label recommendation, MMWR, June 28, 2013, Vol 62, #25
Administer PCV13 vaccine via intramuscular (IM) injection
• Needle gauge: 22–5 gauge
• Needle length*: 5/8–1.5 inch, depending on the patient’s age 
and/or weight 
• Site*: 
oBirth–11 months: Vastus lateralis muscle is preferred
o1–2 years:  Vastus lateralis muscle is preferred; deltoid muscle may 
be used if the muscle mass is adequate 
o3 years and older: Deltoid muscle is preferred; vastus lateralis muscle 
may be used
Administer at the same medical visit as other vaccines except 
MenACWY-D in asplenic persons (others, ok to administer)
Pneumococcal Conjugate (PCV13)
Vaccine Administration  
*Professional judgement should be used to determine the proper needle 
length and site.  Factors influencing site include local reaction, number of 
vaccines to be administered, age, and muscle mass
Recommended for adults 19–64 years at 
increased risk
Routinely recommended for adults age 65 
years or older, 2014 to 2019
Now recommend shared clinical decision 
making before vaccination
ACIP PCV13 Vaccine Recommendations: Adults 
MMWR, October 12, 2012, Vol 61, #40, and MMWR. 2014;63(37);822-5.
Recommended for children 2–18 years at 
increased risk
When both PCV13 and PPSV23 are indicated, 
administer PCV13 first
PCV13 and PPSV23 should not be 
administered at the same visit
ACIP PPSV23 Vaccine Recommendations: Pediatric
Routinely recommended for adults 65 years or 
older at least 1 year after receiving PCV13 
Recommended for adults 19–64 at increased 
risk
When both PCV13 and PPSV23 are indicated, 
administer PCV13 first
PCV13 and PPSV23 should not be 
administered at the same visit
ACIP PPSV23 Vaccine Recommendations: Adults
Routine revaccination of immunocompetent 
persons is not recommended
Revaccination recommended for persons 2–64 
years of age who are at highest risk of serious 
pneumococcal infection
Pneumococcal Polysaccharide Vaccine 
Revaccination
MMWR 2010;59(No.34):1102–5
 5-year interval (2–64 years) with additional dose after 65th 
birthday, 5 years after previous dose:
• Functional or anatomic asplenia (including sickle cell disease)
• Immunosuppression (including HIV infection)
• Transplant
• Chronic renal failure
• Nephrotic syndrome
• Generalized malignancy
• Hematologic malignancy
 1 dose is recommended after the 65th birthday, but only 1 dose 
recommended after 65th birthday
 Maximum 3 doses of PPSV23 in a lifetime
Pneumococcal Polysaccharide Vaccine
Candidates for Revaccination 
MMWR 2010;59(No.34):1102–5 and 2010;59(RR-11)
A 6-year-old patient has sickle cell disease. Her immunization 
history includes a complete PCV13 series and PPSV23 at 4  
years of age. Should PPSV23 be administered today?
• Yes
• No
What Do You Think?
Administer PPSV23 vaccine via intramuscular (IM) or 
subcutaneous injection
• Choose needle size based on route and patient age and/or 
size
• IM Site*: 
o2–3 years: Vastus lateralis muscle is preferred; deltoid muscle may be 
used if the muscle mass is adequate 
o4 years and older: Deltoid muscle is preferred; vastus lateralis muscle 
may be used
• Subcut site: 
o Subcutaneous tissue over the upper outer triceps of arm 
Administer at the same medical visit as other vaccines
Pneumococcal Polysaccharide (PPSV23)
Vaccine Administration  
*Professional judgement should be used to determine the proper needle 
length and site. Factors influencing site include local reaction, number of 
vaccines to be administered, age, and muscle mass
Adults 19 years of age or older with: 
• Immunocompromising conditions
• Functional or anatomic asplenia
• CSF leaks 
• Cochlear implants
Those who have not previously received PCV13 or PPSV23 
should receive a single dose of PCV13 followed by a dose of 
PPSV23 at least 8 weeks later, with a booster dose of PPSV23 
5 or more years later for those with:
• Immunocompromising conditions
• Functional or anatomic asplenia
PCV13 for Immunocompromised Adults*
*MMWR. October 12, 2012;61(40):816–819
PCV13 and PPSV23 adult vaccination recommendations are 
divided between 2 age groups. Persons who are: 
• 19 through 64 years of age
• 65 years of age and older
 Immunization recommendations for persons 19 through        
64 years of age are based on risk, including those at:  
• High risk
• Higher risk
• Highest risk 
Pneumococcal Vaccination and Adults  
MMWR 2015;64(34):944-47
 Administer 1 dose of PPSV23 to adults 19 through 64 years of age at high risk for
IPD
• PCV13 is NOT indicated
 This includes persons with:
• Pulmonary disease (including asthma)
• Cardiac disease (excluding hypertension)
• Liver disease (including cirrhosis)
• Diabetes
• Alcoholism
• Smokers
• Residents of a long-term care facility
High Risk for IPD
MMWR 2015;64(34):944-47
1 dose 
PPSV23 PCV13
8 weeks apart PPSV23PCV13
Administer PCV13 and PPSV23 to adults 19 through 64 years 
of age at higher risk for IPD, including those with: 
• CSF leak
• Cochlear implant
Administer PCV13 followed by PPSV23 vaccine 
Higher Risk for IPD
MMWR 2015;64(34):944–47
Adults 19 through 64 years of age at highest risk for IPD, 
including those who: 
• Are immunocompromised (including HIV infection)
• Have chronic renal  failure or nephrotic syndrome
• Are asplenic
Administer PCV13 and 2 doses of PPSV23 
Highest Risk for IPD
MMWR 2015;64(34):944–47
PPSV23PCV13 8 weeks 5 years PPSV23
PCV13-type disease reduced to historically low levels among 
adults ≥65 years old through pediatric PCV13 use. 
2014 PCV13 recommendation for all adults ≥65 years old:  
minimal impact on PCV13-type disease 
PCV13 is safe and effective 
Balancing this evidence ACIP recommends PCV13 based on 
shared clinical decision making for those ≥65 years old without
• immunocompromising condition
• CSF leak
• cochlear implant.
ACIP still recommends all adults ≥65 years old should receive 
one dose of PPSV23 
New PCV 13 Recommendations for Persons 65 Years and 
Older, June, 2019
Persons Age 65 Years and Older:
PCV13 – Shared clinical decision-making
PPSV23 – recommended for all persons
*8 weeks if at higher or highest risk
MMWR 2015;64(34):944–47
No history of pneumococcal vaccine
Immunization history of PPSV23 at age 65 or older 
PPSV23PCV13
1 year*
1 year PCV13PPSV23
Persons Age 65 Years and Older:
PCV13 – Shared clinical decision-making
PPSV23 – recommended for all persons
*8 weeks if at higher or highest risk
MMWR 2015;64(34):944–47
Received PPSV23 before age 65 years
PPSV23PCV131 year
PPSV23 
before 65 
years
1 year*
Separate doses of PPSV23 by at least 5 years
Vaccine Administration Errors 
Pneumococcal Vaccines  
 Frequent vaccine administration errors: 
• Wrong vaccine
oPPSV23 to an infant 
• Schedule error: 
oMore than 1 PPSV23 revaccination dose to 
immunocompetent at-risk persons
Pneumococcal Vaccines 
Adverse Reactions
PPSV23 PCV13 
 Local reactions 30%–50% 5%–49%
 Fever, myalgia <1% 24–35%
 Febrile seizures ---
Rare:  
1–14/100,000;
with IIV 4–45/ 
100,000
 Severe adverse reactions Rare 8% (local)
 Severe allergic reaction to vaccine component or following 
prior dose of vaccine
Moderate or severe acute illness
Pneumococcal Vaccines
Contraindications and Precautions
 Store PCV13 and PPSV23 
vaccines in a refrigerator 
between 2°C–8°C (36°F–46°F) 
 Store:
• In the original packaging with 
the lids closed
• In a clearly labeled bin and/or 
area of the storage unit—not 
next to each other 
Do not freeze the vaccine
Vaccine Storage and Handling 
Vaccine storage label examples
Available at www.cdc.gov/vaccines/hcp/admin/storage/guide/vaccine-storage-labels.pdf 
PCV13 and PPSV23 should not be administered during the 
same clinic visit 
• Either vaccine may be administered simultaneously with 
influenza vaccine
Administer PCV13 before PPSV23 whenever possible
Administering PCV13 and PPSV23 Vaccines
General Rules
A 70-year-old patient is immunosuppressed. Her 
immunization history includes PCV13 and PPSV23 
administered on the same day at 65 years of age. Should 
PPSV23 be administered today?
• Yes
• No
What Do You Think?
Resources
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 See 
https://www.cdc.gov/vaccines/vpd/pneumo/hcp/recommen
dations.html for updates soon
Resources are being updated
